logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11739302 B1

PDFFull Text
Date of Patent:
Aug. 29, 2023

Filed:

Jul. 13, 2020

Engineered vaccinia virus

Applicant:

Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd., Shenzhen, CN;

Inventor:

Ming Yuan, Shenzhen, CN;

Assignee:

Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd., Shenzhen, CN;

Attorney:
Primary Examiner:

Laura B Goddard

Int. Cl.
CPC ...
C12N 15/863 (2006.01); C12N 7/00 (2006.01); A61K 9/00 (2006.01); A61K 39/395 (2006.01); G01N 33/50 (2006.01); C12Q 1/02 (2006.01); G01N 33/574 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 31/7068 (2006.01); A61K 35/768 (2015.01); A61P 35/00 (2006.01); A61K 31/505 (2006.01); A61K 38/20 (2006.01); A61K 47/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 7/00 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0043 (2013.01); A61K 9/0053 (2013.01); A61K 31/505 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/7068 (2013.01); A61K 35/768 (2013.01); A61K 38/208 (2013.01); A61K 38/2013 (2013.01); A61K 39/3955 (2013.01); A61K 47/00 (2013.01); A61P 35/00 (2018.01); C12Q 1/02 (2013.01); G01N 33/5005 (2013.01); G01N 33/57407 (2013.01); A61K 2039/5252 (2013.01); C12N 2710/24121 (2013.01); C12N 2710/24132 (2013.01);
Abstract

An engineered vaccinia virus, a pharmaceutical composition containing the same, and methods for use in treating a subject in need using the same are provided. The engineered vaccinia virus includes a mutated viral sequence and a heterologous sequence. The mutated viral sequence is used for selective replication in tumor cells and/or activation of immune cells. The heterologous sequence encodes an immune co-stimulatory pathway activating molecule, immunomodulator gene, a truncated viral envelope gene, and/or a tumor suppressor. The heterologous sequence is stably incorporated into the genome of the engineered vaccinia virus. The pharmaceutical composition includes an effective amount of the engineered vaccinia virus and a pharmaceutical acceptable vehicle. The methods for use in treating the subject in need include administering the engineered vaccinia virus to the subject.

Find Patent Forward Citations

Loading…